Coalition for Pulmonary Fibrosis Announces Awards and Activities at ATS International ...(at this year's meeting have included top...),Health

The CPF also awarded an ATS travel grant, provided to fund a PF researcher's conference travel, to James P. Bridges, Ph.D. from Cincinnati Children's Hospital and Medical Center.

For a schedule of ATS events, please visit http://www.thoracic.org/sections/meetings-and-courses/international-conference/2009/index.html.

About Pulmonary Fibrosis (PF)

Pulmonary Fibrosis (PF) is a lung disorder characterized by a progressive scarring -- known as fibrosis -- and deterioration of the lungs, which slowly robs its victims of their ability to breathe. Approximately 128,000 Americans suffer from PF, and there is currently no known cause or cure. An estimated 48,000 new cases are diagnosed each year. PF is difficult to diagnose and an estimated two-thirds of patients die within five years of diagnosis. Sometimes PF can be linked to a particular cause, such as certain environmental exposures, chemotherapy or radiation therapy, residual infection, or autoimmune diseases such as scleroderma or rheumatoid arthritis. However, in many instances, no known cause can be established. When this is the case, it is called idiopathic pulmonary fibrosis (IPF).

About the CPF

The CPF is a 501(c)(3) nonprofit organization, founded in 2001 to accelerate research efforts leading to a cure for pulmonary fibrosis (PF), while educating, supporting, and advocating for the community of patients, families, and medical professionals fighting this disease. The CPF funds promising research int
'/>"/>